Angelini Chiara, Zangrossi Pietro, Mantovani Giorgio, Cavallo Michele Alessandro, De Bonis Pasquale, Scerrati Alba
Department of Neurosurgery, Sant'Anna University Hospital, Ferrara, Italy.
Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Front Neurol. 2024 Feb 7;15:1336760. doi: 10.3389/fneur.2024.1336760. eCollection 2024.
This systematic review aims to investigate a potential correlation between the administration of antiplatelets (APs) or anticoagulants (ACs) and perioperative complications, with a particular focus on hemorrhagic events, in patients undergoing decompressive craniectomy (DC). Additionally, the secondary objective is to assess the neurological outcomes in patients undergoing DC while taking APs/ACs, comparing them to patients not on APs/ACs.
The study utilized PubMed and Science Direct as primary online medical databases for the systematic review. Articles underwent screening based on title, abstract, and full-text review. Four studies meeting the inclusion criteria were selected for comprehensive analysis.
Our findings suggest that the administration of APs/ACs in patients undergoing DC does not significantly impact functional outcomes. Notably, the occurrence of rebleeding within 6 months and other complications, including infections, appears to be less frequent in patients taking APs compared to those not taking APs/ACs.
Literature-derived data on the association between APs/ACs and DC presented considerable heterogeneity and insufficient volume for robust statistical analysis. Consequently, a definitive conclusion regarding the influence of suspending or continuing these therapies on complications and clinical outcomes cannot be confidently reached at present. To address this, a large-scale prospective study is warranted to gather substantial and precise data, facilitating a nuanced understanding of how to balance the risks and benefits associated with antiplatelet and anticoagulant agents in the context of decompressive craniectomy.
本系统评价旨在研究减压颅骨切除术(DC)患者使用抗血小板药物(APs)或抗凝药物(ACs)与围手术期并发症之间的潜在相关性,尤其关注出血事件。此外,次要目的是评估接受DC且正在服用APs/ACs的患者的神经学结局,并与未服用APs/ACs的患者进行比较。
本研究将PubMed和Science Direct作为主要的在线医学数据库用于系统评价。文章根据标题、摘要和全文进行筛选。选择四项符合纳入标准的研究进行综合分析。
我们的研究结果表明,接受DC的患者使用APs/ACs对功能结局没有显著影响。值得注意的是,与未服用APs/ACs的患者相比,服用APs的患者在6个月内再出血及其他并发症(包括感染)的发生率似乎更低。
关于APs/ACs与DC之间关联的文献数据存在相当大的异质性,且数量不足,无法进行有力的统计分析。因此,目前无法就暂停或继续这些治疗对并发症和临床结局的影响得出明确结论。为此,有必要开展一项大规模前瞻性研究,以收集大量准确的数据,从而更细致地了解如何在减压颅骨切除术的背景下平衡抗血小板和抗凝药物相关的风险与益处。